AN2 Therapeutics (ANTX) Net Cash Flow (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Net Cash Flow for 6 consecutive years, with $33.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 2599.7% year-over-year to $33.5 million; the TTM figure through Mar 2026 stood at $33.5 million (up 815.8% YoY), while the FY2025 annual figure was -$1.4 million, down 124.72% from the prior year.
• Net Cash Flow grew to $33.5 million in Q1 2026 per ANTX's latest filing, from $1.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $70.4 million in Q1 2022 and bottomed at -$41.9 million in Q2 2022.
• Historically, Net Cash Flow has averaged $2.4 million across 5 years, with a median of -$510000.0 in 2023.
• Annual changes were most pronounced in 2023 — Net Cash Flow tumbled 973.22% — and 2026, when it surged 2599.7%.
• AN2 Therapeutics' Net Cash Flow stood at -$1.6 million in 2022, then sank by 973.22% to -$17.0 million in 2023, then rose by 28.56% to -$12.1 million in 2024, then surged by 115.97% to $1.9 million in 2025, then soared by 1630.96% to $33.5 million in 2026.
• Business Quant data shows ANTX's Net Cash Flow at $33.5 million in Q1 2026, $1.9 million in Q4 2025, and -$217000.0 in Q3 2025.